CIL Demonstrates Ongoing Investment in Xenia, Ohio Facility Through Recent Land Acquisition
Cambridge Isotope Laboratories, Inc. (CIL) has recently expanded its Xenia, Ohio location by acquiring an additional 14.8 acres of land. This strategic move was made to facilitate easier access to utilities for future expansion, according to Mike Steiger, Vice President of Engineering and Project Execution at CIL.
The newly acquired land is adjacent to the 20 acres purchased in 2017, which currently houses the North Star expansion project. This project, which has just been completed, is set to significantly boost the production of Carbon-13 (13C) and is currently in the startup phase. The North Star expansion is hailed as the largest 13C separation facility ever built, further enhancing CIL’s capacity to meet the growing demand for this stable isotope.
CEO Cliff Caldwell emphasized the importance of this expansion in meeting the increasing global demand for stable isotopes in various applications. The acquisition of this land showcases CIL’s dedication to innovation and growth to better serve its customers by ensuring reliable production of isotopically labeled compounds.
The CIS facility, where the expansion took place, boasts the world’s largest 13C separation facility, is among the biggest 18O isotope-separation facilities globally, and houses the largest commercial D2O re-enrichment columns.
Stable isotopes, particularly deuterium, have witnessed a surge in commercial applications in recent years spanning pharmaceuticals, semiconductors, and high-technology sectors. CIL has secured long-term supply contracts for D2O and maintains significant supply reserves across multiple locations to ensure a steady supply for its customers.
Cambridge Isotope Laboratories, Inc. is a leading global supplier of stable isotopes and isotopically labeled compounds for various industries. The company, owned by Otsuka Pharmaceutical, has operations in the United States, Canada, China, Germany, and France. For more details on CIL, visit their website at isotope.com.
For further information, contact Crissy Krisko at crissyk@isotope.com or 1.978.269.1930.
This strategic expansion by Cambridge Isotope Laboratories, Inc. highlights the company’s commitment to meeting the evolving needs of its customers and solidifying its position as a leader in the stable isotopes market.
